Pfizer Inc. is hoping to use its tafamidis co-pay support plan as the vehicle to try to halt the US government’s targeting of charity assistance programs for Medicare patients as a violation of the Anti-Kickback Statute (AKS).
The pharma industry has been roiled by government investigations of its charity copayments with 11 companies, including Pfizer, reaching settlements...





